mutLBSgeneDB |
Gene summary for CYP2A6 |
![]() |
Basic gene Info. | Gene symbol | CYP2A6 |
Gene name | cytochrome P450, family 2, subfamily A, polypeptide 6 | |
Synonyms | CPA6|CYP2A|CYP2A3|CYPIIA6|P450C2A|P450PB | |
Cytomap | UCSC genome browser: 19q13.2 | |
Type of gene | protein-coding | |
RefGenes | NM_000762.5, | |
Description | 1,4-cineole 2-exo-monooxygenasecoumarin 7-hydroxylasecytochrome P450 2A6cytochrome P450 IIA3cytochrome P450(I)cytochrome P450, subfamily IIA (phenobarbital-inducible), polypeptide 6flavoprotein-linked monooxygenasexenobiotic monooxygenase | |
Modification date | 20141207 | |
dbXrefs | MIM : 122720 | |
HGNC : HGNC | ||
Ensembl : ENSG00000255974 | ||
HPRD : 00420 | ||
Vega : OTTHUMG00000182713 | ||
Protein | UniProt: P11509 go to UniProt's Cross Reference DB Table | |
Expression | CleanEX: HS_CYP2A6 | |
BioGPS: 1548 | ||
Pathway | NCI Pathway Interaction Database: CYP2A6 | |
KEGG: CYP2A6 | ||
REACTOME: CYP2A6 | ||
Pathway Commons: CYP2A6 | ||
Context | iHOP: CYP2A6 | |
ligand binding site mutation search in PubMed: CYP2A6 | ||
UCL Cancer Institute: CYP2A6 | ||
Assigned class in mutLBSgeneDB | B: This gene belongs to targetable_mutLBSgenes. |
![]() |
GO ID | GO Term | PubMed ID | GO:0009804 | coumarin metabolic process | 19651758 | GO:0017144 | drug metabolic process | 19651758 | GO:0042738 | exogenous drug catabolic process | 15680923 | GO:0046226 | coumarin catabolic process | 19029318 |
Top |
Ligand binding site mutations for CYP2A6 |
![]() |
LBS | AAchange of nsSNV | Cancer type | # samples | I366 | D364A | BRCA | 1 | Q360 | R361I | COAD | 1 | R101 | E103K | COAD | 1 | G301 | G301W | COAD | 1 | G441 | E442Q | LUAD | 1 | V306 | V306I | LUAD | 1 | S369 | M368T | LUSC | 1 | F209 | G207V | SKCM | 1 | N297 | T295M | UCEC | 1 | R437 | R437W | UCEC | 1 | L395 | P393H | UCEC | 1 | V116 | V116M | UCEC | 1 |
cf) Cancer type abbreviation. BLCA: Bladder urothelial carcinoma, BRCA: Breast invasive carcinoma, CESC: Cervical squamous cell carcinoma and endocervical adenocarcinoma, COAD: Colon adenocarcinoma, GBM: Glioblastoma multiforme, LGG: Brain lower grade glioma, HNSC: Head and neck squamous cell carcinoma, KICH: Kidney chromophobe, KIRC: Kidney renal clear cell carcinoma, KIRP: Kidney renal papillary cell carcinoma, LAML: Acute myeloid leukemia, LUAD: Lung adenocarcinoma, LUSC: Lung squamous cell carcinoma, OV: Ovarian serous cystadenocarcinoma, PAAD: Pancreatic adenocarcinoma, PRAD: Prostate adenocarcinoma, SKCM: Skin cutaneous melanoma, STAD: Stomach adenocarcinoma, THCA: Thyroid carcinoma, UCEC: Uterine corpus endometrial carcinoma. |
Top |
Protein structure related information for CYP2A6 |
![]() Mupro score denotes assessment of the effect of mutations on thermodynamic stability. (ΔΔE<0: mutation decreases stability, ΔΔE>0: mutation increases stability) |
![]() ![]() |
![]() |
![]() Blue: mutations of positive stability change. and red : the most recurrent mutation for this gene. |
LBS | AAchange of nsSNV | Relative stability change | Q360 | R361I | -1.3237857 | R101 | E103K | -1.1487635 | V116 | V116M | -1.0648213 | V306 | V306I | -0.89644112 | L395 | P393H | -0.86832604 | S369 | M368T | -0.7997672 | N297 | T295M | -0.64990759 | I366 | D364A | -0.5965848 | R437 | R437W | -0.56449858 | G301 | G301W | -0.46187381 | F209 | G207V | -0.28524299 | G441 | E442Q | -0.10550226 |
(MuPro1.1: Jianlin Cheng et al., Prediction of Protein Stability Changes for Single-Site Mutations Using Support Vector Machines, PROTEINS: Structure, Function, and Bioinformatics. 2006, 62:1125-1132) |
![]() |
Top |
Differential gene expression and gene-gene network for CYP2A6 |
![]() |
![]() |
Top |
Top |
Phenotype information for CYP2A6 |
![]() |
Disease ID | Disease name | # PubMed | Association type |
umls:C0024121 | Lung Neoplasms | 9 | AlteredExpression, Biomarker, GeneticVariation |
umls:C0040336 | Tobacco Use Disorder | 5 | Biomarker, GeneticVariation |
umls:C0001418 | Adenocarcinoma | 4 | Biomarker, GeneticVariation |
umls:C0279626 | Esophageal Squamous Cell Carcinoma | 3 | Biomarker, GeneticVariation |
umls:C0009404 | Colorectal Neoplasms | 2 | AlteredExpression, Biomarker |
umls:C0262584 | Carcinoma, Small Cell | 2 | Biomarker |
umls:C0019196 | Hepatitis C | 2 | Biomarker |
umls:C0038356 | Stomach Neoplasms | 2 | Biomarker |
umls:C1861063 | TOBACCO ADDICTION, SUSCEPTIBILITY TO | 2 | Biomarker, Therapeutic |
umls:C0034067 | Pulmonary Emphysema | 1 | Biomarker |
umls:C0006111 | Brain Diseases | 1 | Biomarker |
umls:C0206704 | Carcinoma, Large Cell | 1 | Biomarker |
umls:C0242656 | Disease Progression | 1 | Biomarker |
umls:C0860207 | Drug-Induced Liver Injury | 1 | Biomarker |
umls:C0019163 | Hepatitis B | 1 | Biomarker |
umls:C0023897 | Liver Diseases, Parasitic | 1 | Biomarker |
umls:C0027439 | Nasopharyngeal Neoplasms | 1 | Biomarker |
umls:C0029106 | Opisthorchiasis | 1 | Biomarker |
umls:C0033578 | Prostatic Neoplasms | 1 | Biomarker |
![]() |
Allele ID | AA change | Clinical significance | Origin | Phenotype IDs |
Top |
Pharmacological information for CYP2A6 |
![]() Heatmap showing the correlation between gene expression and drug response across all the cell-lines. We chose the top 20 among 138 drugs.We used Pearson's correlation coefficient. |
![]() |
![]() |
![]() |
![]() |
Drug status | DrugBank ID | Name | Type | Drug structure |
Experimental | DB04665 | 2H-1-BENZOPYRAN-2-ONE | Small molecule | ![]() |
Experimental | DB07609 | N,N-DIMETHYL(5-(PYRIDIN-3-YL)FURAN-2-YL)METHANAMINE | Small molecule | ![]() |
Experimental | DB07617 | N-METHYL(5-(PYRIDIN-3-YL)FURAN-2-YL)METHANAMINE | Small molecule | ![]() |
Experimental | DB07621 | (5-(PYRIDIN-3-YL)FURAN-2-YL)METHANAMINE | Small molecule | ![]() |
Experimental | DB07623 | 4,4'-DIPYRIDYL DISULFIDE | Small molecule | ![]() |
![]() |
![]() |
![]() |
Ligand ID | Ligand short name | Ligand long name | PDB ID | PDB name | mutLBS | SNE | SABINENE | (1S,5S)-4-METHYLIDENE-1-(PROPAN-2-YL) BICYCLO[3.1.0]HEXANE | 4rui | A | F209 G301 | SNE | SABINENE | (1S,5S)-4-METHYLIDENE-1-(PROPAN-2-YL) BICYCLO[3.1.0]HEXANE | 4rui | C | F209 G301 | SNE | SABINENE | (1S,5S)-4-METHYLIDENE-1-(PROPAN-2-YL) BICYCLO[3.1.0]HEXANE | 4rui | E | F209 G301 | D1G | N,N-DIMETHYL(5-(PYRIDIN-3-YL)FURAN-2-YL)METHANAMINE | 2fdu | A | F209 N297 G301 | D1G | N,N-DIMETHYL(5-(PYRIDIN-3-YL)FURAN-2-YL)METHANAMINE | 2fdu | B | F209 N297 G301 | D1G | N,N-DIMETHYL(5-(PYRIDIN-3-YL)FURAN-2-YL)METHANAMINE | 2fdu | C | F209 N297 G301 | D1G | N,N-DIMETHYL(5-(PYRIDIN-3-YL)FURAN-2-YL)METHANAMINE | 2fdu | D | F209 N297 G301 | D2G | N-METHYL(5-(PYRIDIN-3-YL)FURAN-2-YL)METHANAMINE | 2fdv | A | F209 N297 G301 | D2G | N-METHYL(5-(PYRIDIN-3-YL)FURAN-2-YL)METHANAMINE | 2fdv | B | F209 N297 G301 | D2G | N-METHYL(5-(PYRIDIN-3-YL)FURAN-2-YL)METHANAMINE | 2fdv | C | F209 N297 G301 | D2G | N-METHYL(5-(PYRIDIN-3-YL)FURAN-2-YL)METHANAMINE | 2fdv | D | F209 N297 G301 | D3G | (5-PYRIDIN-3-YLFURAN-2-YL)METHANAMINE | 2fdw | A | F209 N297 G301 | D3G | (5-PYRIDIN-3-YLFURAN-2-YL)METHANAMINE | 2fdw | C | F209 N297 G301 | D4G | 4,4'-DITHIODIPYRIDINE | 2fdy | A | F209 N297 G301 | D4G | 4,4'-DITHIODIPYRIDINE | 2fdy | B | F209 N297 G301 | D4G | 4,4'-DITHIODIPYRIDINE | 2fdy | C | F209 N297 G301 | D4G | 4,4'-DITHIODIPYRIDINE | 2fdy | D | F209 N297 G301 | 9PL | (+)-PILOCARPINE | 3t3r | A | F209 N297 G301 | 9PL | (+)-PILOCARPINE | 3t3r | B | F209 N297 G301 | 9PL | (+)-PILOCARPINE | 3t3r | C | F209 N297 G301 | 9PL | (+)-PILOCARPINE | 3t3r | D | F209 N297 G301 | NCT | (S)-NICOTINE | 4ejj | C | F209 N297 G301 | SNE | SABINENE | (1S,5S)-4-METHYLIDENE-1-(PROPAN-2-YL) BICYCLO[3.1.0]HEXANE | 4rui | D | F209 N297 G301 | SNE | SABINENE | (1S,5S)-4-METHYLIDENE-1-(PROPAN-2-YL) BICYCLO[3.1.0]HEXANE | 4rui | B | F209 N297 G301 | SNE | SABINENE | (1S,5S)-4-METHYLIDENE-1-(PROPAN-2-YL) BICYCLO[3.1.0]HEXANE | 4rui | F | F209 N297 G301 | D3G | (5-PYRIDIN-3-YLFURAN-2-YL)METHANAMINE | 2fdw | B | F209 N297 G301 I366 | D3G | (5-PYRIDIN-3-YLFURAN-2-YL)METHANAMINE | 2fdw | D | F209 N297 G301 I366 | NCT | (S)-NICOTINE | 4ejj | A | F209 N297 G301 I366 | 9PL | (+)-PILOCARPINE | 3t3q | A | F209 N297 I366 | 9PL | (+)-PILOCARPINE | 3t3q | B | F209 N297 I366 | 9PL | (+)-PILOCARPINE | 3t3q | C | F209 N297 I366 | 9PL | (+)-PILOCARPINE | 3t3q | D | F209 N297 I366 | N4E | PHENACETIN | 3ebs | A | N297 | N4E | PHENACETIN | 3ebs | D | N297 | COU | COUMARIN | 1z10 | A | N297 G301 | COU | COUMARIN | 1z10 | B | N297 G301 | COU | COUMARIN | 1z10 | C | N297 G301 | COU | COUMARIN | 1z10 | D | N297 G301 | 8MO | METHOXSALEN | 1z11 | A | N297 G301 I366 | 8MO | METHOXSALEN | 1z11 | B | N297 G301 I366 | 8MO | METHOXSALEN | 1z11 | C | N297 G301 I366 | 8MO | METHOXSALEN | 1z11 | D | N297 G301 I366 | NCT | (S)-NICOTINE | 4ejj | D | N297 G301 I366 | N4E | PHENACETIN | 3ebs | B | N297 I366 | HEM | HEME B | 1z10 | C | R101 G301 L395 R437 G441 | HEM | HEME B | 1z10 | D | R101 G301 Q360 L395 R437 G441 | HEM | HEME B | 1z11 | A | R101 G301 Q360 L395 R437 G441 | HEM | HEME B | 1z11 | D | R101 G301 Q360 L395 R437 G441 | HEM | HEME B | 2fdw | C | R101 G301 Q360 L395 R437 G441 | HEM | HEME B | 1z11 | B | R101 G301 Q360 S369 L395 R437 G441 | HEM | HEME B | 4rui | D | R101 G301 Q360 S369 L395 R437 G441 | HEM | HEME B | 4rui | A | R101 G301 V306 I366 S369 L395 R437 G441 | HEM | HEME B | 2fdy | C | R101 G301 V306 L395 R437 G441 | HEM | HEME B | 4ejj | C | R101 G301 V306 L395 R437 G441 | HEM | HEME B | 3t3r | B | R101 G301 V306 Q360 I366 L395 R437 G441 | HEM | HEME B | 4ejj | B | R101 G301 V306 Q360 I366 S369 L395 R437 G441 | HEM | HEME B | 1z10 | B | R101 G301 V306 Q360 L395 R437 G441 | HEM | HEME B | 1z11 | C | R101 G301 V306 Q360 L395 R437 G441 | HEM | HEME B | 2fdu | C | R101 G301 V306 Q360 L395 R437 G441 | HEM | HEME B | 2fdu | D | R101 G301 V306 Q360 L395 R437 G441 | HEM | HEME B | 2fdw | A | R101 G301 V306 Q360 L395 R437 G441 | HEM | HEME B | 2fdw | D | R101 G301 V306 Q360 L395 R437 G441 | HEM | HEME B | 2fdy | A | R101 G301 V306 Q360 L395 R437 G441 | HEM | HEME B | 3t3r | C | R101 G301 V306 Q360 L395 R437 G441 | HEM | HEME B | 4rui | B | R101 G301 V306 Q360 L395 R437 G441 | HEM | HEME B | 1z10 | A | R101 G301 V306 Q360 S369 L395 R437 G441 | HEM | HEME B | 2fdu | A | R101 G301 V306 Q360 S369 L395 R437 G441 | HEM | HEME B | 2fdu | B | R101 G301 V306 Q360 S369 L395 R437 G441 | HEM | HEME B | 2fdv | A | R101 G301 V306 Q360 S369 L395 R437 G441 | HEM | HEME B | 3t3r | D | R101 G301 V306 Q360 S369 L395 R437 G441 | HEM | HEME B | 4rui | F | R101 G301 V306 Q360 S369 L395 R437 G441 | HEM | HEME B | 2fdy | D | R101 G301 V306 S369 L395 R437 G441 | HEM | HEME B | 4ejj | D | R101 G301 V306 S369 L395 R437 G441 | HEM | HEME B | 4rui | C | R101 G301 V306 S369 L395 R437 G441 | HEM | HEME B | 2fdw | B | R101 V116 G301 Q360 L395 R437 G441 | HEM | HEME B | 4ejj | A | R101 V116 G301 S369 L395 R437 G441 | HEM | HEME B | 4rui | E | R101 V116 G301 V306 Q360 S369 R437 G441 | HEM | HEME B | 3t3r | A | R101 V116 G301 V306 S369 L395 R437 G441 | HEM | HEME B | 3t3q | D | R101 V116 Q360 L395 R437 G441 | HEM | HEME B | 3t3q | A | R101 V116 V306 Q360 L395 R437 G441 | HEM | HEME B | 3t3q | C | R101 V116 V306 Q360 L395 R437 G441 | HEM | HEME B | 3t3q | B | R101 V306 L395 R437 G441 | HEM | HEME B | 3ebs | C | R101 V306 Q360 I366 L395 R437 G441 | HEM | HEME B | 3ebs | D | R101 V306 Q360 I366 L395 R437 G441 | HEM | HEME B | 2fdv | C | R101 V306 Q360 L395 R437 G441 | HEM | HEME B | 3ebs | A | R101 V306 Q360 L395 R437 G441 | HEM | HEME B | 3ebs | B | R101 V306 Q360 L395 R437 G441 | HEM | HEME B | 2fdv | B | R101 V306 Q360 S369 L395 R437 G441 | HEM | HEME B | 2fdv | D | R101 V306 Q360 S369 L395 R437 G441 | HEM | HEME B | 2fdy | B | R101 V306 Q360 S369 L395 R437 G441 |
Top |
Conservation information for LBS of CYP2A6 |
![]() |
LBS | AA sequence | # species | Species |
![]() |
Copyright © 2016-Present - The University of Texas Health Science Center at Houston |